Neurosurgery in India

Neurosurgical capacity is the practical draw. India trains a large number of neurosurgeons and its major units operate daily, so a tumour that would sit on a list for months elsewhere gets a date in weeks. For a growing lesion, the calendar is not an administrative detail — it is part of the clinical picture.

Cost follows the same pattern as the rest of Indian surgery. A craniotomy for tumour that runs $50,000-$100,000 in the United States is typically $4,500-$8,000 here, and aneurysm treatment shows a similar gap. Because neurosurgical admissions can extend unpredictably, the ratio matters more in this field than in most: an extra week of neuro-ICU is survivable financially here in a way it often is not elsewhere.

The units we work with also do the unglamorous part properly — neuro-rehabilitation. After tumour or stroke surgery, physiotherapy, speech therapy and occupational therapy are what convert a technically successful operation into a functional recovery, and having them in the same building rather than referred out three weeks later makes a measurable difference.

The caution here is specific: not every brain lesion should be operated on. A brainstem tumour, a diffuse low-grade glioma in an eloquent area, or an incidental small meningioma in an elderly patient may be better watched or irradiated. A surgeon who recommends observation is not being unhelpful.

Neurosurgical outcomes resist averaging more than almost any other field. A meningioma over the convexity and a glioblastoma crossing the midline are both "brain tumour surgery" and share nothing else — not the operation, not the risk, not the prognosis. Any single percentage covering both is meaningless.

What can be said: for elective surgery on an accessible, benign tumour in a fit patient, high-volume units report mortality well under 2% and most patients leave hospital within a week. Aneurysm clipping and coiling in the elective, unruptured setting have low complication rates; after a subarachnoid haemorrhage the picture changes completely, and the outcome is driven far more by the grade of the bleed than by anything the surgeon does afterwards.

The risk that matters most to patients is usually neurological deficit rather than mortality — weakness, speech difficulty, visual field loss. Ask specifically: what deficit is likely, what is possible, and how much of it typically recovers over six months? That is a harder question than "what is your success rate", and the quality of the answer tells you a lot about the surgeon.